Low-Dose Aspirin May Reduce Cancer Risk

Low-dose aspirin, a common strategy for preventing cardiovascular disease, can also reduce nonvascular deaths, including cancer deaths. Edward J. Mills, from the University of Ottawa (Canada), and colleagues completed a meta-analysis of 10 electronic databases, pooling data from randomized clinical trials evaluating low-dose (75-325 mg) daily aspirin. The tam found that the studies demonstrated a significant treatment effect after approximately 4 years of follow-up.  The study authors conclude that: “Nonvascular deaths, including cancer deaths, are reduced with low-dose aspirin.”